The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

Also called NCT01062763

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 119 participants (enrolled count) (from the registry)
Sponsor
Ib Abildgaard Jacobsen (from the registry)
Registry
  • NCT NCT01062763
  • EudraCT 2009-017033-22
Other papers using this trial's data
  • Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension Journal of human hypertension, 2015-01 DOI, PubMed 24739800

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01062763. Randomized; quadruple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-05-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
Acronym
SDHDS
Condition
Arterial Hypertension
Condition
Hypertension, Resistant to Conventional Therapy
Condition
Diabetes Mellitus
Intervention (Drug)
spironolactone
Intervention (Drug)
placebo
Lead sponsor
Ib Abildgaard Jacobsen (class: other)

Record details

Record id
cardio:ct-nct01062763
Content hash
6def9bfe575837325e2d5325b7c539c28095811c62242af12df173240380f832